Cancer / Oncology/Triple-negative breast cancer
Breast · subtype
Triple-negative breast cancer
Subtype of Breast cancer
Clinical / Scientific
TNBC lacks ER, PR and HER2 and is enriched for TP53 mutation, homologous-recombination defects, MYC activity, and, in a subset, immune infiltration. PARP biology is relevant in BRCA-associated cases. and programmes are often prominent.
Core Biological Drivers
TP53 mutation
Near-ubiquitous in basal-like TNBC.
HRD / BRCA
Homologous-recombination deficiency in a subset.
MYC and glycolysis
Biomass and Warburg programmes.
EMT / stemness
Claudin-low and mesenchymal features in a subset.
Key Pathways
Scientific explanation
TP53 encodes a stress-responsive factor controlling cell-cycle arrest, and metabolic adaptation. Loss or mutation is among the most common cancer events.
Scientific explanation
Homologous-recombination defects (BRCA1/2 and related) create dependence on PARP-mediated repair. Mismatch-repair deficiency creates hypermutation and immune visibility.
Scientific explanation
MYC factors coordinate biomass accumulation, ribosome biogenesis, and glutamine use. Amplification or pathway activation is common.
Scientific explanation
Aerobic (Warburg metabolism) supports ATP, biomass and redox buffering even when oxygen is available. Hexokinase, PKM2 and lactate export are frequent nodes.
Scientific explanation
phosphorylates PIP2 to PIP3, recruiting . supports growth, survival, glucose uptake and mTORC1 input. Pathway activation is common via PIK3CA mutation, PTEN loss or -tyrosine- signalling.
Scientific explanation
family ligands drive endothelial sprouting and vascular permeability, a canonical tumour axis.
Scientific explanation
PD-1 on T cells engaging PD-L1/PD-L2 restrains cytotoxic function. Tumour or myeloid PD-L1 is a canonical adaptive immune-evasion axis.
Scientific explanation
Epithelial–mesenchymal plasticity, driven by TWIST/SNAIL/ZEB and TGF-β/Wnt/Notch inputs, reduces adhesion and increases motility and stem-like features.
Scientific explanation
Stem-like programmes (Wnt, Notch, Hedgehog, ALDH, CD44) can support self-renewal, quiescence and therapy tolerance in a minority population.
Scientific explanation
is iron-dependent lipid-peroxidation cell death opposed by GPX4 and cystine/GSH supply. Some therapy-resistant and mesenchymal states show altered sensitivity.
Scientific explanation
ABC transporters such as ABCB1/P-gp, ABCC1 and ABCG2 export structurally diverse drugs and contribute to multidrug-resistance phenotypes.
Pathway Convergence
Target → pathway → downstream effect → biological consequence. Shared intersections are mechanistic maps, not protocols.
Growth-factor signalling
Ligand or mutation-driven RTK input feeds PI3K/AKT and mTORC1, supporting anabolic growth. This is a map of signalling, not a treatment protocol.
Hypoxia to vessels
Low oxygen stabilizes HIF-1α, inducing VEGF and endothelial sprouting. Anti-angiogenic pharmacology intersects this axis but does not erase the tumour ecosystem.
Inflammatory survival
Chronic cytokine tone activates NF-κB and STAT3 transcriptional programmes that favour survival, invasion and sometimes immune evasion.
Mitochondrial stress
Electron-transport stress raises ROS; NRF2-driven transcription can buffer that stress and support survival. Antioxidant interventions are dual-edged.
Metabolic Vulnerabilities
Aerobic supports ATP, biomass and acidification even when oxygen is available. Extent varies by tumour and remains a vulnerability hypothesis rather than a uniform target.
Glutamine anaplerosis and nucleotide nitrogen demand are prominent in MYC-high and rapidly proliferating tumours. Dependence is heterogeneous.
Some TNBC models show OXPHOS-high residual fractions after therapy stress.
Tumor Microenvironment
Disordered vasculature creates , HIF-1α stabilization, induction and immune-suppressive adenosine/lactate milieus.
Tumour-associated macrophages and myeloid-derived suppressor cells secrete cytokines that support invasion and blunt cytotoxic T cells.
Metastasis Module
, protease-mediated invasion, , circulating tumour-cell survival and organ-specific colonization form the metastatic cascade. Pre-metastatic niches and vascular permeability influence tropism.
Resistance Biology
Drug efflux, DNA-repair restoration, CSC-like quiescence and metabolic switching are documented resistance themes.
Cancer Stemness
Wnt, Notch, Hedgehog, ALDH and CD44-associated programmes can mark stem-like fractions with quiescence and therapy tolerance. These markers are not interchangeable across tumour types.
Mechanism-Based Adjunctive Strategies
Compounds appear only where a mechanistic overlap exists for this cancer. Evidence tiers are not equivalent. Nothing here is a treatment recommendation.
Target / Mechanism
Modest complex I inhibition raises AMP:ATP, activating and restraining hepatic and -linked anabolism. Direct antineoplastic efficacy is not established from that pharmacology alone.
Cancer relevance
activation and restraint provide a metabolic rationale in - and -linked tumours. Human data are mixed and do not establish metformin as cancer therapy.
Metabolic adjunctive research context. Convergence: AMPK, mTOR, Glycolysis.
Target / Mechanism
Benzimidazole that binds β-. Mammalian disruption, mitotic arrest and related signalling in cancer models are preclinical and are not an approved anticancer use.
Cancer relevance
disruption can trigger mitotic stress and in cell and animal models. This is not an established oncology use.
Experimental antimitotic / microtubule stress. Convergence: Apoptosis, p53.
Target / Mechanism
Veterinary benzimidazole with and experimental glucose-transport effects in cell models. Not an established human antineoplastic.
Cancer relevance
Veterinary benzimidazole with preclinical and glucose-handling reports. Human oncology evidence is insufficient.
Preclinical microtubule hypothesis. Convergence: Apoptosis, Glycolysis.
Target / Mechanism
Lysosomotropic agent that raises endosomal/autophagosomal pH, impairing flux. Combination trials in oncology have been mixed; blockade is not equivalent to proven benefit.
Cancer relevance
Lysosomal pH elevation impairs flux. Early combination trials exist; benefit is not established and toxicity/retinal risk remain labelled concerns.
Autophagy-modulation research combinations. Convergence: Autophagy.
Disulfiram
Target / Mechanism
ALDH ; copper-complexed forms can inhibit proteasome and NF-κB-related survival programmes in models. Clinical oncology evidence remains limited.
Cancer relevance
ALDH and copper-dependent proteasome/NF-κB stress in models; clinical oncology remains limited.
ALDH / redox experimental context. Convergence: Cancer stemness, NF-κB, Oxidative stress.
Target / Mechanism
Tetracycline antibiotic that can inhibit matrix metalloproteinases and, at experimental exposures, protein synthesis. Oncology uses remain investigational.
Cancer relevance
MMP inhibition and experimental effects map to invasion and stem-like states in models.
Anti-invasive / mitochondrial experimental context. Convergence: Invasion, Cancer stemness, Mitochondrial oxidative phosphorylation.
Curcumin
Target / Mechanism
Polyphenol with promiscuous in-vitro NF-κB, and ROS effects. Bioavailability is poor; dish activity does not establish clinical anticancer efficacy.
Cancer relevance
In-vitro NF-κB/ effects are frequent. Poor bioavailability and absence of robust clinical anticancer efficacy keep this pathway-level.
Inflammatory-signalling dish models. Convergence: NF-κB, JAK/STAT.
Target / Mechanism
uncoupler in cestodes; mammalian models report , Wnt/β-catenin and modulation. Those host-signalling findings are investigational/preclinical.
Cancer relevance
Models report Wnt/β-catenin, and effects. Host signalling findings remain investigational.
Wnt / STAT3 signalling models. Convergence: Wnt/β-catenin, JAK/STAT, mTOR.
Target / Mechanism
AMP mimetic that activates in experimental systems. Research tool, not an approved oncology medicine.
Cancer relevance
Pharmacologic activation is a research tool.
Experimental AMPK agonism. Convergence: AMPK, mTOR.
Target / Mechanism
Cysteine donor replenishing glutathione. Redox buffering can be protective or, in some models, support tumour antioxidant capacity. Dual-edged; not an antineoplastic.
Cancer relevance
GSH repletion is dual-edged in oncology models and must not be framed as anticancer.
Redox-buffering cautionary context. Convergence: Oxidative stress, NRF2, Ferroptosis.
Research Context
- Breast portraits. Perou CM, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-752. https://doi.org/10.1038/35021093
- Hallmarks. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674. https://doi.org/10.1016/j.cell.2011.02.013
- Warburg. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029-1033. https://doi.org/10.1126/science.1160809
- Resistance. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13(10):714-726. https://doi.org/10.1038/nrc3599
This oncology atlas is educational. Pathway maps, adjunctive strategies, and compound listings describe mechanistic relevance. They do not establish clinical efficacy, do not recommend treatment, and are not a substitute for oncology care. Evidence tiers are not equivalent.